COUR Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Myasthenia Gravis

COUR Pharmaceuticals, a clinical-stage biotechnology company developing novel immune-modifying nanoparticles designed to reprogram the immune system for the treatment of autoimmune disorders (COUR NanoParticles or CNPs), today announced that the U.S. Food and Drug Administration has cleared an Investigational New Drug (IND) application to initiate a Phase 1b/2a proof-of-concept study of COUR’s investigational therapy, CNP-106.